ARTV Insider Notice: 25,500 Common Shares from RSUs Listed for Sale
Rhea-AI Filing Summary
Artiva Biotherapeutics reported a Form 144 notice showing a planned sale of 25,500 common shares held as Restricted Stock Units that were acquired and are to be sold on 08/15/2025. The broker listed is Morgan Stanley Smith Barney LLC and the planned transaction lists an aggregate market value of $68,850 based on 25,500 shares. The filing records 24,425,762 shares outstanding and identifies NASDAQ as the exchange. The filer reports no securities sold in the prior three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.
The notice appears routine: shares arose from company RSUs, the sale is executed through a major broker, and there are no prior sales reported in the three-month lookback period.
Positive
- Transaction is clearly documented with acquisition date, nature (RSUs), broker, and sale date provided
- No prior sales in the past three months, suggesting this is a scheduled disposition rather than frequent insider trading
- Sale size is small relative to shares outstanding (~0.10%), limiting immediate dilutive impact
Negative
- None.
Insights
TL;DR Routine insider sale of RSU shares through a broker; modest size relative to outstanding shares.
The filing documents a proposed sale of 25,500 shares from Restricted Stock Units, with an aggregate market value of $68,850. Compared with 24.4 million shares outstanding, the sale is immaterial in dilution terms (~0.10% of outstanding shares). The use of a major broker and the absence of sales in the prior three months point to a scheduled, non-urgent disposition rather than an emergency liquidity event. For investors, this is a routine insider liquidity action with limited direct impact on capitalization or control.
TL;DR Form 144 conforms to Rule 144 reporting requirements; no red flags in the notice.
The notice indicates shares were acquired and paid on the same date (RSU vesting on 08/15/2025) and that the seller affirms no material nonpublic information. The filing shows "Nothing to Report" for sales in the prior three months and specifies the broker and NASDAQ as venue. From a compliance perspective, the form contains the expected elements: acquisition details, amount, broker, and certifications. There is no indication of irregular transaction structure or contingent payment arrangements.